SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is seeing significant investor attention driven by upcoming Phase 3 clinical data readouts expected later this year, alongside heightened interest in the psychedelic sector following recent regulatory developments. While many in the community remain bullish on the potential for a major market re-rate, active discussions are focused on the company's substantial cash burn rate, persistent dilution concerns, and the lack of open-market insider buying.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining momentum as investors rotate into Japanese blockchain and IoT-focused projects, fueling renewed speculation about the token's role in the evolving data-economy ecosystem. The community is actively discussing technical breakouts and long-term utility potential, with sentiment shifting toward bullish as trading volume shows a notable increase.

Genius Sports Ltd. engages in the provision of scalable, technology-led products and services to the sports, sports betting, and sports media industries. It also involves in Sports League, which offers technology infrastructure for the collection, integration, and distribution of live data; Sportsbooks, which includes collection of live sports data, odds making, risk management and player marketing; and Sports Media, which provides a range of online marketing and fan engagement tools. The company was founded by Mark Adrian Locke in 2000 and is headquartered in London, United Kingdom.

Genius Sports Limited

Genius Sports is gaining significant community attention as shareholders focus on its critical role as infrastructure for the expanding prediction markets sector and its strategic pivot toward high-growth advertising and fan engagement. Investors are particularly bullish on the companys ability to monetize official data and fan insights, viewing the current stock price as undervalued despite broader market volatility and regulatory discussions.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is drawing investor attention as the community debates the impact of ongoing token emissions versus potential catalysts like regulatory shifts and new mobile application launches. Discussions remain polarized, with many investors expressing frustration over price stagnation and supply dilution while others highlight the asset's underlying exchange utility and the recent emergence of native meme coins on the Cronos blockchain.

Oatly Group AB is a holding company, which focuses on developing expertise around oats, a global power crop with inherent properties suited for sustainability and human health. It operates through the following geographical segments: Europe & International, North America and Greater China. The company was founded by Björn Öste in 1994 and is headquartered in Malmö, Sweden.

Oatly Group AB - ADR

Oatly Group

Oatly is trending as investors monitor ongoing strategic reviews, including a potential China carve-out that could improve the balance sheet and reduce debt exposure. The community is actively discussing product expansion into new markets and retail channels like Costco, while also debating the stock's volatility and the impact of its current low market capitalization.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid intense community debate over leaked details of a potential ceasefire agreement with Iran and ongoing skepticism regarding the company's valuation. Traders are actively discussing the impact of these geopolitical negotiations and high-profile company events on the stock's long-term market performance.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is currently trending as investors weigh strong quarterly growth and record backlogs against a large shelf offering that has created short-term supply overhang concerns. Community members are heavily debating the valuation of the space sector ahead of the SpaceX IPO, with many viewing the recent volatility as a buying opportunity for long-term data and analytics exposure.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Semiconductor stocks remain the central focus of market conversation as investors weigh explosive AI-driven growth against technical exhaustion and concerns about crowded positioning. Community debate remains split between those riding the massive momentum in chip ETFs and skeptics warning that the current pace of capital expenditure in AI infrastructure is reaching a speculative bubble peak.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is facing heavy selling pressure as investors react to management's warnings regarding industry-wide supply chain constraints, despite the company delivering strong earnings and raising its guidance. While the stock has seen a sharp pullback, the community is actively debating whether this is a structural weakness or a temporary 'buy the dip' opportunity for a foundational player in the AI data center infrastructure space.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing high volatility as investors track a potential take-private buyout led by Nelson Peltz and Trian Partners, further fueled by a significant short interest exceeding 30% of the float. The community remains actively focused on recent leadership changes, the upcoming dividend, and the potential for a massive short squeeze if a premium acquisition offer is finalized.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What's Going On With Immix Biopharma Stock Thursday?

Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028. Read the details.read more...

The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Immix Biopharma (NASDAQ:IMMX) Trading Down 4.6%  - Time to Sell?

Immix Biopharma (NASDAQ:IMMX) Shares Down 4.6% - Time to Sell...

Immix Biopharma (NASDAQ:IMMX) Trading 12% Higher - Should You Buy?

Immix Biopharma (NASDAQ:IMMX) Stock Price Up 12% - Still a Buy...

Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat reports. One...

Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says

Mizuho raised their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Monday...

Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus...

Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX)

Citizens Jmp restated a "market outperform" rating and set a $23.00 price target on shares of Immix Biopharma in a research report on Friday...

Immix Biopharma (NASDAQ:IMMX) Given New $15.00 Price Target at HC Wainwright

HC Wainwright lifted their price objective on shares of Immix Biopharma from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday...

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

IMMXImmix Biopharma Inc

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest IMMX News